Last reviewed · How we verify
Trastuzumab/Hyaluronidase-oysk
Trastuzumab/Hyaluronidase-oysk is a Monoclonal antibody Small molecule drug developed by National Cancer Institute (NCI). It is currently in Phase 3 development for Adjuvant treatment of HER2-positive breast cancer, Treatment of HER2-positive metastatic breast cancer. Also known as: Herceptin Hylecta, Trastuzumab and Hyaluronidase, Trastuzumab and Hyaluronidase-oysk, Trastuzumab and Recombinant Human Hyaluronidase PH20.
Trastuzumab targets the HER2/neu receptor, while hyaluronidase is an enzyme that helps the drug spread more evenly throughout the body.
Trastuzumab targets the HER2/neu receptor, while hyaluronidase is an enzyme that helps the drug spread more evenly throughout the body. Used for Adjuvant treatment of HER2-positive breast cancer, Treatment of HER2-positive metastatic breast cancer.
At a glance
| Generic name | Trastuzumab/Hyaluronidase-oysk |
|---|---|
| Also known as | Herceptin Hylecta, Trastuzumab and Hyaluronidase, Trastuzumab and Hyaluronidase-oysk, Trastuzumab and Recombinant Human Hyaluronidase PH20, Trastuzumab and rHuPH20 |
| Sponsor | National Cancer Institute (NCI) |
| Drug class | Monoclonal antibody |
| Target | HER2/neu receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Trastuzumab is a monoclonal antibody that binds to the HER2/neu receptor on cancer cells, which can help slow or stop the growth of these cells. Hyaluronidase is an enzyme that breaks down hyaluronic acid, a substance that can make it difficult for the drug to spread evenly throughout the body. By breaking down this substance, hyaluronidase helps the drug reach the cancer cells more effectively.
Approved indications
- Adjuvant treatment of HER2-positive breast cancer
- Treatment of HER2-positive metastatic breast cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Abdominal pain
- Injection site reaction
Key clinical trials
- Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (PHASE3)
- A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) (PHASE2)
- The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trastuzumab/Hyaluronidase-oysk CI brief — competitive landscape report
- Trastuzumab/Hyaluronidase-oysk updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI
Frequently asked questions about Trastuzumab/Hyaluronidase-oysk
What is Trastuzumab/Hyaluronidase-oysk?
How does Trastuzumab/Hyaluronidase-oysk work?
What is Trastuzumab/Hyaluronidase-oysk used for?
Who makes Trastuzumab/Hyaluronidase-oysk?
Is Trastuzumab/Hyaluronidase-oysk also known as anything else?
What drug class is Trastuzumab/Hyaluronidase-oysk in?
What development phase is Trastuzumab/Hyaluronidase-oysk in?
What are the side effects of Trastuzumab/Hyaluronidase-oysk?
What does Trastuzumab/Hyaluronidase-oysk target?
Related
- Drug class: All Monoclonal antibody drugs
- Target: All drugs targeting HER2/neu receptor
- Manufacturer: National Cancer Institute (NCI) — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Adjuvant treatment of HER2-positive breast cancer
- Indication: Drugs for Treatment of HER2-positive metastatic breast cancer
- Also known as: Herceptin Hylecta, Trastuzumab and Hyaluronidase, Trastuzumab and Hyaluronidase-oysk, Trastuzumab and Recombinant Human Hyaluronidase PH20, Trastuzumab and rHuPH20
- Compare: Trastuzumab/Hyaluronidase-oysk vs similar drugs
- Pricing: Trastuzumab/Hyaluronidase-oysk cost, discount & access